Approximately 15% of non-small cell lung cancers have a mutation in a growth receptor called EGFR, causing tumor cells to grow uncontrollably. Researchers developed an effective drug that inhibits EGFR and kills cancer cells, but the tumor grows back later. Sordella wanted to understand the molecular mechanisms behind this relapse and how to prevent it.

Sordella and her team discovered that a small percentage of drug-resistant cancer cells were already present before treatment. Instead of relying on EGFR, these cells are dependent on another gene (AXL) for survival. Furthermore, they observed that the cells could transition between these drug-sensitive and drug-resistant "states." When patients finish EGFR treatment, random modifications constantly occur in the remaining cells, causing both types of cells to grow back.

Sordella and her team worked with clinicians at Northwell Health and former CSHL Professor Gregory Hannon, now at the Cancer Research UK Cambridge Institute. Hannon's research focuses on microRNA, a molecule that regulates cells by managing transcribed (copied) genes. Sordella explains:

"The genome is like a library. So when you have to do a recipe to bake something, you go there, you transcribe your recipe, you take it out from the library, you go in the kitchen. What these microRNAs do, they intercept all the recipes that are getting out from your library. And then, they decide whether this is a recipe that the cell should care about or not. So they are what they call 'gatekeepers' of a cell state."

The researchers discovered that a certain microRNA called miR335 determines the "state" of the cancer cell. If the cancer cell loses miR335, a cascade of events is triggered that allows cells to use the alternative AXL pathway; the cells are not killed by drugs that target EGFR. These drug-resistant cells survive and eventually, the tumor grows back.

Understanding how resistance arises in lung cancer is key to figuring out how to eliminate a tumor. Sordella hopes that these findings could help develop treatments to wipe out both AXL- and EGFR-dependent cells from the start.

Story Source:

Materials provided by Cold Spring Harbor Laboratory. Original written by Jasmine Lee. Note: Content may be edited for style and length.

Journal Reference:

1. Polona Safaric Tepes, Debjani Pal, Trine Lindsted, Ingrid Ibarra, Amaia Lujambio, Vilma Jimenez Sabinina, Serif Senturk, Madison Miller, Navya Korimerla, Jiahao Huang, Lawrence Glassman, Paul Lee, David Zeltsman, Kevin Hyman, Michael Esposito, Greg Hannon, Raffaella Sordella. An epigenetic switch regulates the ontogeny of AXL positive/EGFR-TKI resistant cells by modulating miR-335 expression. eLife, 2021; 10 DOI: 10.7554/eLife.66109